Carboxymethyl kappa-carrageenan polyelectrolyte multilayers: anticoagulant blood-compatible coatings as sustainable alternatives to heparin for blood-contacting surfaces.

Liszt Y C Madruga, Somayeh Baghersad, Paulo C F da Câmara, Roberta M Sabino, Matt J Kipper, Ketul C Popat

Abstract readPreprint

In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Liszt Y C MadrugaDepartment of Chemical and Biological Engineering, Colorado State University, Fort Collins, CO 80526, USA.

Somayeh BaghersadSchool of Biomedical Engineering, Colorado State University, Fort Collins, CO 80526, USA.

Paulo C F da CâmaraLaboratory of Petroleum Research, LAPET, Institute of Chemistry, Federal University of Rio Grande do Norte, UFRN, 59078-970 Natal, RN, Brazil.

Roberta M SabinoDepartment of Chemical and Biomedical Engineering, University of Wyoming, Laramie, WY, 82071, USA.

Matt J KipperDepartment of Chemical and Biological Engineering, Colorado State University, Fort Collins, CO 80526, USA.

Ketul C PopatSchool of Biomedical Engineering, Colorado State University, Fort Collins, CO 80526, USA.

Funding

Nanostructured Surfaces With Improved HemocompatibilityR21EB033511 · NIBIB · GEORGE MASON UNIVERSITY · PI KIPPER, MATTHEW, POPAT, KETUL CHANDRAKANT · 2022 to 2023

$410k

NIBIB NIH HHS R21 EB033511

6 · The paper itself

Abstract

This research introduces carboxymethyl kappa-carrageenan-chitosan polyelectrolyte multilayers as a promising and sustainable alternative to heparin, used in surface treatments for blood-contacting medical devices. The polysaccharide-based surface coatings have good cytocompatibility and resist microbial adhesion of both Pseudomonas aeruginosa and Staphylococcus aureus. The blood compatibility of surfaces containing carboxymethyl-kappa-carrageenan was directly compared to similar polyelectrolyte multilayers containing heparin. The carboxymethyl-kappa-carrageenan surfaces inhibit whole-blood clotting like heparin-containing surfaces. Blood clotting is mediated by both protein-surface and cell-surface interactions. The carboxymethyl-kappa-carrageenan surfaces adsorb more fibrinogen and less albumin than the heparin surfaces, and they also exhibit reduced platelet and leukocyte adhesion, compared to heparin surfaces. These results suggest that carboxymethyl-kappa-carrageenan may represent a sustainable alternative to heparin as an anticoagulant surface modification.

Identifiers

PMID40799733

DOI10.21203/rs.3.rs-7014360/v1

PMCPMC12340928

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.